Caribou Biosciences Advances CAR-T Therapy Trials

Caribou Biosciences ( (CRBU) ) has shared an announcement.

Caribou Biosciences announced the initiation of the GALLOP Phase 1 clinical trial for CB-010 in lupus patients and provided significant updates on its CAR-T cell therapy programs for hematologic malignancies. The company plans to present data from several Phase 1 trials and potentially begin a pivotal Phase 3 trial in 2025, contingent on positive results. These developments are expected to enhance Caribou’s position in the allogeneic CAR-T cell therapy market, offering broader patient access and quicker treatment availability.

More about Caribou Biosciences

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company operating in the CRISPR genome-editing industry. It focuses on developing allogeneic CAR-T cell therapies for treating hematologic malignancies and autoimmune diseases. Their key products include CB-010, CB-011, and CB-012, which are in various stages of clinical trials.

YTD Price Performance: -2.38%

Average Trading Volume: 1,506,138

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $148.5M

For a thorough assessment of CRBU stock, go to TipRanks’ Stock Analysis page.